Repository landing page
Clin Infect Dis
Abstract
We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).CC999999/ImCDC/Intramural CDC HHSUnited States/2022-08-29T00:00:00Z34893821PMC91842981188- Article
- small molecule kinase inhibitors
- ibrutinib
- invasive fungal infections
- cancer
- opportunistic infections
- Adenine
- Humans
- Incidence
- Invasive Fungal Infections
- Piperidines
- United States
- Article
- small molecule kinase inhibitors
- ibrutinib
- invasive fungal infections
- cancer
- opportunistic infections
- Adenine
- Humans
- Incidence
- Invasive Fungal Infections
- Piperidines
- United States
Similar works
This paper was published in CDC Stacks.
Having an issue?
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.